The group's principal activities are to develop and commercialize non-prescription therapeutics and nutraceutical drugs designed to prevent inflammation and their sequelae and also to develop cosmetics for skin conditions. The group is a development stage company that plans to develop new drugs internally. The drugs are intended to be used in the control of conditions such as skin wrinkles and surgical adhesions. The technology also has applicability in the cosmetic and nutraceutical markets and agents for wrinkles and other conditions are being developed for these markets. The group from the past several months has decided to pursue other business opportunities.
